Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)

References

• National Institute of Infectious Diseases. COVID-19 vaccine (as of May 10, 2021). Availabel at: https://www.niid.go.jp/niid/images/vaccine/covid19_vaccine_20210510.pdf. Accessed 2022 Dec 4
   Google Scholar
• Maeda H, Saito N, Igarashi A, et al. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the delta variant epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Clin Infect Dis. 2022;75:1971–1979.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407–1416.
   PubMed Web of Science ®Google Scholar
• Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by covid-19 vaccines. N Engl J Med. 2022;386:340–350.
   PubMed Web of Science ®Google Scholar
• Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021;385:e85.
   PubMed Web of Science ®Google Scholar
• National Institute of Infectious Diseases. COVID-19 vaccine (as of December 16, 2021). Availabel at: https://www.niid.go.jp/niid/images/vaccine/covid19_vaccine_20211216.pdf. Accessed 2022 Dec 4
   Google Scholar
• Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in Southern Africa. Nature. 2022;603:679–686.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Shaw RH, Supasa P, et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet. 2022;399:234–236.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022;386:1532–1546.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022;28:1063–1071.
   PubMed Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. N Engl J Med. 2022;386:1804–1816.
   PubMed Web of Science ®Google Scholar
• Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and delta variants. JAMA. 2022;327:639–651.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Lbour and Welfare. Asymptomatic carriers of SARS-COV-2 in airport quarantine, November 30, 2021 2021. Availabel at: https://www.mhlw.go.jp/stf/newpage_22507.html. Accessed 2022 Dec 4
   Google Scholar
• Ministry of Health, Lbour and Welfare. Visualizing the data: information on COVID-19 infections. Available at: https://covid19.mhlw.go.jp/en/. Accessed 2022 Dec 4
   Google Scholar
• Ministry of Health, Lbour and Welfare. Materials of advisory board on countermeasures to combat novel coronavirus infections 2022 Availabel at: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00333.html. Accessed 2022 Dec 4
   Google Scholar
• VERSUS Group. Vaccine effectiveness real-time surveillance for SARS-CoV-2 Availabel at: http://www.tm.nagasaki-u.ac.jp/versus/about.html. Accessed 2022 Dec 4
   Google Scholar
• World Health Organization. Evaluation of COVID-19 vaccine effectiveness. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.1. Accessed 2023 Feb 24
   Google Scholar
• Ministry of Health, Lbour and Welfare. Approval information for diagnostic tests for SARS-CoV-2 Availabel at: https://www.mhlw.go.jp/stf/newpage_11331.html#Nucleic. Accessed 2022 Dec 4
   Google Scholar
• Lai MY, Bukhari FDM, Zulkefli NZ, et al. Clinical testing on SARS-CoV-2 swab samples using reverse-transcription loop-mediated isothermal amplification (RT-LAMP). BMC Infect Dis. 2022;22:697.
   PubMed Web of Science ®Google Scholar
• Subali AD, Wiyono L. Reverse transcriptase loop mediated isothermal amplification (RT-LAMP) for COVID-19 diagnosis: a systematic review and meta-analysis. Pathog Glob Health. 2021;115:281–291.
   PubMed Web of Science ®Google Scholar
• Ulhaq ZS, Soraya GV. The diagnostic accuracy of seven commercial molecular in vitro SARS-CoV-2 detection tests: a rapid meta-analysis. Expert Rev Mol Diagn. 2021;21:733–740.
   PubMed Web of Science ®Google Scholar
• Schneider M, Iftner T, Ganzenmueller T. Evaluation of the analytical performance and specificity of a SARS-CoV-2 transcription-mediated amplification assay. J Virol Methods. 2021;294:114182.
   PubMed Web of Science ®Google Scholar
• Hirotsu Y, Maejima M, Shibusawa M, et al. Direct comparison of xpert xpress, filmarray respiratory panel, lumipulse antigen test, and RT-qPCR in 165 nasopharyngeal swabs. BMC Infect Dis. 2022;22:221.
   PubMed Web of Science ®Google Scholar
• Hirotsu Y, Sugiura H, Maejima M, et al. Comparison of roche and lumipulse quantitative SARS-CoV-2 antigen test performance using automated systems for the diagnosis of COVID-19. Int J Infect Dis. 2021;108:263–269.
   PubMed Web of Science ®Google Scholar
• National Institute of Infectious Diseases. List of vaccines available in Japan. Availabel at: https://www.niid.go.jp/niid/images/vaccine/corona_vaccine/covid19vac_list_20221013.pdf. Accessed 2022 Dec 4
   Google Scholar
• Prime Minister of Japan and His Cabinet. COVID-19 Vaccines. Availabel at: https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html. Accessed 2022 Dec 4
   Google Scholar
• Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172:577–582.
   PubMed Web of Science ®Google Scholar
• Buchan SA, Chung H, Brown KA, et al. Estimated effectiveness of COVID-19 vaccines against omicron or delta symptomatic infection and severe outcomes. JAMA Network Open. 2022;5:e2232760.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Puzniak L, et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. Lancet Respir Med. 2022;10:689–699.
   PubMed Web of Science ®Google Scholar
• National Institute of Infectious Diseases. Report on seroepidemiological surveillance for SARS-CoV-2 infections in 2021 in Japan. Availabel at: https://www.niid.go.jp/niid/images/epi/corona/79/covid19-79.pdf. Accessed 2022 Dec 4
   Google Scholar
• UK Health Security Agency. COVID-19 vaccine surveillance report Week 17 Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1072064/Vaccine-surveillance-report-week-17.pdf. Accessed 2022 Dec 4
   Google Scholar
• Clarke KEN, Jones JM, Deng Y, et al. Seroprevalence of infection-induced SARS-CoV-2 antibodies - United States, September 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71:606–608.
   PubMed Web of Science ®Google Scholar
• Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N Engl J Med. 2022;387:21–34.
   PubMed Web of Science ®Google Scholar
• Chin ET, Leidner D, Lamson L, et al. Protection against Omicron from vaccination and previous infection in a prison system. N Engl J Med. 2022;387:1770–1782.
   PubMed Web of Science ®Google Scholar
• National Institute of Infectious Diseases. Test-negative case-control study to evaluate COVID-19 vaccines. Available at: https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/10966-covid19-71.html. Accessed 2023 Feb 24
   Google Scholar
• Monge S, Rojas-Benedicto A, Olmedo C, et al. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study. Lancet Infect Dis. 2022;22:1313–1320.
   PubMed Web of Science ®Google Scholar
• Sheikh A, Kerr S, Woolhouse M, et al. Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect Dis. 2022;22:959–966.
   PubMed Web of Science ®Google Scholar
• Yu J, Collier AY, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. N Engl J Med. 2022;386:1579–1580.
   PubMed Web of Science ®Google Scholar
• Chemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nat Commun. 2022;13:3082.
   PubMed Web of Science ®Google Scholar
• Kirsebom FCM, Andrews N, Stowe J, et al. COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England. Lancet Infect Dis. 2022;22:931–933.
   PubMed Web of Science ®Google Scholar
• Link-Gelles R, Levy ME, Gaglani M, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION network, 10 States, December 2021-June 2022. MMWR Morb Mortal Wkly Rep. 2022;71: 931-9.
   Web of Science ®Google Scholar